ORCID: https://orcid.org/0000-0002-5053-1462; Zwergal, Andreas
ORCID: https://orcid.org/0000-0002-3839-8398; Lehrer, Nicole; Hansel, Nedda; Näher, Marius; Thiessen, Franziska; Dieterich, Marianne
ORCID: https://orcid.org/0000-0001-9903-9594 und Huppert, Doreen
ORCID: https://orcid.org/0000-0002-1473-5898
(2026):
Superior oblique myokymia: diagnostic criteria and long-term outcome.
In: Journal of Neurology, Vol. 273, No. 4, 242
[PDF, 1MB]
Abstract
Background: Superior oblique myokymia (SOM) is a rare disorder characterized by brief episodes of high-frequency, low-amplitude monocular nystagmus frequently caused by vascular contact with the trochlear nerve. Comprehensive analyses of SOM symptomatology and long-term progression are limited. No diagnostic criteria are available.
Methods: Adult patients who were diagnosed with SOM between 2008 and 2024 were asked to complete a detailed questionnaire on disease symptomatology, time course, and medication. The impact of the disease on patient-reported functioning was assessed using a Likert scale. In addition, medical records were screened in all patients.
Results: A total of 35 patients with SOM were identified (21 females; mean age at symptom onset 42.8 ± 15.0 years). 30 patients experienced visuo-perceptual symptoms (i.e., diplopia or oscillopsia, 85.7%), 22 patients ocular motor symptoms (i.e., noticeable “eye-twitching”, 62.9%), and 15 patients dizziness or gait instability (42.9%). Of 22 patients analyzed for their long-term therapeutic outcome, 13 described symptom improvement with pharmacotherapy, and six without pharmacotherapy. Patients experienced a moderate to high impact of the disease on their daily private and professional lives. Based on these findings, specific diagnostic criteria for SOM were proposed.
Conclusions: SOM can substantially impair patients’ quality of life and daily functioning. The long-term course appears favorable, with most patients experiencing either complete remission or significant symptom reduction over time. Pharmaceutical treatment proved effective in nearly 90% of patients, and spontaneous remission was also observed. Further research should focus on larger patient cohorts defined by clear diagnostic criteria to enhance understanding of SOM’s natural history and treatment outcomes.
| Item Type: | Journal article |
|---|---|
| Faculties: | Medicine > Munich Cluster for Systems Neurology (SyNergy) Medicine > Medical Center of the University of Munich > Neurological Clinic and Polyclinic with Friedrich Baur Institute Medicine > Medical Center of the University of Munich > German Center for Vertigo and Balance Disorders |
| Research Centers: | Graduate School of Systemic Neurosciences (GSN) |
| Subjects: | 500 Science > 570 Life sciences; biology 600 Technology > 610 Medicine and health |
| URN: | urn:nbn:de:bvb:19-epub-135434-5 |
| ISSN: | 0340-5354 |
| Language: | English |
| Item ID: | 135434 |
| Date Deposited: | 30. Apr 2026 14:19 |
| Last Modified: | 30. Apr 2026 14:19 |
| DFG: | Gefördert durch die Deutsche Forschungsgemeinschaft (DFG) - 390857198 |
